Voyager Therapeutics Inc. (VYGR)
Voyager Therapeutics Statistics
Share Statistics
Voyager Therapeutics has 55.21M shares outstanding. The number of shares has increased by 1.5% in one year.
Shares Outstanding | 55.21M |
Shares Change (YoY) | 1.5% |
Shares Change (QoQ) | 1.06% |
Owned by Institutions (%) | 59.65% |
Shares Floating | 44.89M |
Failed to Deliver (FTD) Shares | 137 |
FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 2.93M, so 5.32% of the outstanding shares have been sold short.
Short Interest | 2.93M |
Short % of Shares Out | 5.32% |
Short % of Float | 6.33% |
Short Ratio (days to cover) | 9.15 |
Valuation Ratios
The PE ratio is -5.03 and the forward PE ratio is -2.13. Voyager Therapeutics's PEG ratio is 0.04.
PE Ratio | -5.03 |
Forward PE | -2.13 |
PS Ratio | 4.09 |
Forward PS | 2.9 |
PB Ratio | 1.09 |
P/FCF Ratio | -17.36 |
PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Voyager Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.56, with a Debt / Equity ratio of 0.15.
Current Ratio | 5.56 |
Quick Ratio | 5.56 |
Debt / Equity | 0.15 |
Debt / EBITDA | -0.53 |
Debt / FCF | -2.32 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $465.12K |
Profits Per Employee | $-377.92K |
Employee Count | 172 |
Asset Turnover | 0.2 |
Inventory Turnover | n/a |
Taxes
Income Tax | 665K |
Effective Tax Rate | -1.03% |
Stock Price Statistics
The stock price has increased by -52.29% in the last 52 weeks. The beta is 1.02, so Voyager Therapeutics's price volatility has been higher than the market average.
Beta | 1.02 |
52-Week Price Change | -52.29% |
50-Day Moving Average | 3.75 |
200-Day Moving Average | 5.87 |
Relative Strength Index (RSI) | 52.72 |
Average Volume (20 Days) | 375.37K |
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 80M and earned -65M in profits. Earnings per share was -1.13.
Revenue | 80M |
Gross Profit | 80M |
Operating Income | -83.29M |
Net Income | -65M |
EBITDA | -83.29M |
EBIT | -83.29M |
Earnings Per Share (EPS) | -1.13 |
Balance Sheet
The company has 71.37M in cash and 43.73M in debt, giving a net cash position of 27.64M.
Cash & Cash Equivalents | 71.37M |
Total Debt | 43.73M |
Net Cash | 27.64M |
Retained Earnings | -326.18M |
Total Assets | 393.05M |
Working Capital | 227.02M |
Cash Flow
In the last 12 months, operating cash flow was -15.31M and capital expenditures -3.52M, giving a free cash flow of -18.83M.
Operating Cash Flow | -15.31M |
Capital Expenditures | -3.52M |
Free Cash Flow | -18.83M |
FCF Per Share | -0.33 |
Margins
Gross margin is 100%, with operating and profit margins of -104.11% and -81.25%.
Gross Margin | 100% |
Operating Margin | -104.11% |
Pretax Margin | -80.42% |
Profit Margin | -81.25% |
EBITDA Margin | -104.11% |
EBIT Margin | -104.11% |
FCF Margin | -23.54% |
Dividends & Yields
VYGR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for VYGR is $12, which is 239% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 239% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Scores
Altman Z-Score | 0.23 |
Piotroski F-Score | 3 |